Recent studies on protein kinase signaling inhibitors based on thiazoles: review to date

Manal S. Ebaid, Hoda Atef Abdelsattar Ibrahim, Asmaa F. Kassem and Ahmed Sabt

RSC Adv., 2024, 14, 36989
DOI: 10.1039/D4RA05601A

Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS

Sadaf Dorandish, Komal Bhayekar, Anuradha Singh, Narva Deshwar Kushwaha, Evan Malin, Sara Serafimovski, Jeremy M. Kelm, Navnath S. Gavande and Naga Rajiv Lakkaniga

RSC Med. Chem., 2025
DOI: 10.1039/D5MD00169B

Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation

Sarah Pogash and Steven Fletcher

RSC Med. Chem., 2025, 16, 2958
DOI: 10.1039/D5MD00095E

Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c‐KIT, and RET Anti‐Targets

Desmond Akwata, Allison L. Kempen, Neetu Dayal, Nickolas R. Brauer and Herman O. Sintim

ChemMedChem, 2024, 19
DOI: 10.1002/cmdc.202300442

Advances in the design and discovery of next-generation janus kinase-2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms

Safa Daoud and Mutasem Omar Taha

Expert Opinion on Drug Discovery, 2024, 19, 1403
DOI: 10.1080/17460441.2024.2417368

Therapeutic approaches targeting oncogenic proteins in myeloid leukemia: challenges and perspectives

Xing Yi Yan, Yuan Yuan Kang, Ze Yan Zhang, Ping Huang, Chang Yang and Hua Naranmandura

Expert Opinion on Therapeutic Targets, 2024, 28, 1131
DOI: 10.1080/14728222.2024.2443577

Flavones, Flavonols, Lignans, and Caffeic Acid Derivatives from Dracocephalum moldavica and Their In Vitro Effects on Multiple Myeloma and Acute Myeloid Leukemia

Karin Jöhrer, Mayra Galarza Pérez, Brigitte Kircher and Serhat Sezai Çiçek

IJMS, 2022, 23, 14219
DOI: 10.3390/ijms232214219

Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML

Nada Alaa El‐Deen, RosaAnna DeFilippis, Amal Kamal Abdel‐Aziz, Sandra N. Milik, Suhana Patel, Muhammad I. Ismail, Omar Khaled, Tarek Erfan Ahmed, Ayatullah Gamal Abdelfattah, Eslam M. H. Ali, Maiy Y. Gaballah, Martin J. McPhillie, Khaled A. M. Abouzid, Rabah A. T. Serya, Maged Henary, Saverio Minucci, Neil P. Shah and Eman M. E. Dokla

Archiv der Pharmazie, 2025, 358
DOI: 10.1002/ardp.70002

Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review

Fariba Peytam, Zahra Emamgholipour, Alireza Mousavi, Mahfam Moradi, Roham Foroumadi, Loghman Firoozpour, Fatemeh Divsalar, Maliheh Safavi and Alireza Foroumadi

Bioorganic Chemistry, 2023, 140, 106831
DOI: 10.1016/j.bioorg.2023.106831

Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia

Hend A. A. Ezelarab, Taha F. S. Ali, Samar H. Abbas, Heba A. Hassan and Eman A. M. Beshr

BMC Chemistry, 2023, 17
DOI: 10.1186/s13065-023-00981-8

The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN–GIL hybrid single-molecule inhibitors

Christopher C. Goodis, Christian Eberly, Alexandria M. Chan, MinJung Kim, Brandon D. Lowe, Curt I. Civin and Steven Fletcher

European Journal of Medicinal Chemistry, 2025, 285, 117190
DOI: 10.1016/j.ejmech.2024.117190

Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases

Robert Roskoski

Pharmacological Research, 2024, 199, 107036
DOI: 10.1016/j.phrs.2023.107036

IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid Leukemia

Scott B. Hoyt, Chris J. Finocchio, Elizabeth Croll, Gregory J. Tawa, Mingliang Zhang, Jiangong Wang, Huixi Li, Li Ma, Kaikai Li, Xiaohu Zhang, Xin Xu, Pranav Shah, Yuhong Fang, Lyndsey C. Bolanos, Gabriel Gracia-Maldonado, Amal Kolt, Christina Robinson, Jessica Free, Elijah F. Edmondson, Simone Difilippantonio, LaQuita M. Jones, Ashley E. Culver-Cochran, Jan S. Rosenbaum, Daniel T. Starczynowski and Craig J. Thomas

ACS Med. Chem. Lett., 2025, 16, 887
DOI: 10.1021/acsmedchemlett.5c00147

A Review of FLT3 Kinase Inhibitors in AML

Cristina Negotei, Andrei Colita, Iuliana Mitu, Anca Roxana Lupu, Mihai-Emilian Lapadat, Constanta Elena Popovici, Madalina Crainicu, Oana Stanca and Nicoleta Mariana Berbec

JCM, 2023, 12, 6429
DOI: 10.3390/jcm12206429

Mechanisms associated with t(7;12) acute myeloid leukaemia: from genetics to potential treatment targets

Denise Ragusa, Liza Dijkhuis, Cristina Pina and Sabrina Tosi

Bioscience Reports, 2023, 43
DOI: 10.1042/BSR20220489

Gilteritinib Reduces FLT3 Expression in Acute Myeloid Leukemia Cells

Thị Lam Thái and Sun-Young Han

Biomol Ther (Seoul), 2024, 32, 577
DOI: 10.4062/biomolther.2023.215

Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges

Jan Rataj, Lukas Gorecki, Darina Muthna, Ales Sorf, Vladimir Krystof, Pavel Klener, Martina Ceckova, Martina Rezacova and Jan Korabecny

Biomedicine & Pharmacotherapy, 2025, 182, 117788
DOI: 10.1016/j.biopha.2024.117788

Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia

Scott B. Hoyt, Chris J. Finocchio, Elizabeth Croll, Gregory J. Tawa, Huixu Li, Li Ma, Kaikai Li, Li Liu, Ranran Li, Xiaohu Zhang, Kelli Wilson, Xin Xu, Pranav Shah, Jordan Williams, Yuhong Fang, Lyndsey C. Bolanos, Gabriel Gracia-Maldonado, Amal Kolt, Christina Robinson, Jessica Free, Elijah F. Edmondson, Simone Difilippantonio, LaQuita M. Jones, Ashley E. Culver-Cochran, Jan S. Rosenbaum, Daniel T. Starczynowski and Craig J. Thomas

ACS Med. Chem. Lett., 2024, 15, 1843
DOI: 10.1021/acsmedchemlett.4c00269

Molecular precision medicine: Multi-omics-based stratification model for acute myeloid leukemia

Teng Wang, Siyuan Cui, Chunyi Lyu, Zhenzhen Wang, Zonghong Li, Chen Han, Weilin Liu, Yan Wang and Ruirong Xu

Heliyon, 2024, 10, e36155
DOI: 10.1016/j.heliyon.2024.e36155

Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review

Lukas Gorecki, Eva Reznickova, Vladimir Krystof, Martina Rezacova, Martina Ceckova and Jan Korabecny

Expert Opinion on Therapeutic Patents, 2025, 35, 137
DOI: 10.1080/13543776.2024.2446224